발기부전으로 음경해면체내 Trimix 주사치료법을 장기간 사용하는 환자의 성생활 및 만족도 = Patients’ Satisfaction and Quality of Sex Life in Patients Undergoing Long-term Intracavernous Injections with Trimix

다국어 초록 (Multilingual Abstract)

Purpose: Intracaverous injections (ICI) are the standard treatment for erectile dysfunction (ED) when oral

phosphodiesterase 5 inhibitors (PDE5I) fail or are contraindicated. However, many patients are wary of

ICI because of aversion to the injection. We assessed patients' satisfaction and the quality of the sex life

in patients undergoing long-term ICI with trimix.

Materials and Methods: One hundred five patients with ED who had used ICI with trimix for at least

6 months were enrolled in the study. We investigated the Erectile Dysfunction Inventory of Treatment

Satisfaction Questionnaire (EDITS), quality of sex life, and pain on injection and erection. The EDITS

questions were scored on a 0 to 4-point scale and the mean scores were multiplied by 25 to normalize the

scores to a 100-point scale and to create the EDITS index. A total score > 50 was defined as “satisfied

with treatment” and a score of < 50 was defined as “not satisfied with treatment.”

Results: The mean age of the patients was 70±8.2 years, the mean duration of ED was 6.4±3.3 years,

and the mean duration of ICI treatment was 50.3±32.6 months. Of the 105 patients, 48.5% had received

PDE5I treatment prior to ICI treatment. Among the 51 patients who had received PDE5I, 72.5% (37/51)

and 19.6% (10/51) discontinued PDE5I due to inefficacy and side effects, respectively. Four patients used

PDE5I in combination with ICI. The mean number of injections was 2.99±1.26 per month and the mean

dose of trimix was 0.33±0.14 ml per injection. The mean EDITS index was 73.7±14.5, and 93% of the patients

were classified in the satisfaction group according to the EDITS index criteria. Patients noted an improvement

in their sex life (78.1%), their relationship with their partner (68.6%), and their quality of life

(65.7%) after using ICI with trimix; 92.3% of patients responded that they were ready to recommend ICI

with trimix to their friends. The mean scores for pain on injection and erection were 1.04/10 and 0.98/10,

respectively.

참고문헌 (Reference)

• 1 Lee, H.Y., "Vasoactive drug self-injection into corpus cavernosum in erectile impotence" 4 : 13-22, 1986
• 2 Ahn, T.Y., "Trimix intracavernous injection therapy in patients with erectile dysfunction" 36 : 651-657, 1995
• 3 Andersson, K.E., "The effect of sildenafil on apomorphine-evoked increases in intracavernous pressure in the awake rat" 161 : 1707-1712, 1999
• 4 Rendell, M.S., "Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group" 281 : 421-426, 1999
• 5 Lewis, R., "Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire" 57 : 960-965, 2001
• 6 Moon, D.G., "New Cocktails for intracavernous injections using KATP channel opener, Pinacidil" 17 : 163-170, 1999
• 7 Fallon, B., "Intracavernous injection therapy for male erectile dysfunction" 22 : 833-845, 1995
• 8 Virag, R., "Intracavernous injection of papaverine as a diagnostic and therapeutic method in erectile failure" 35 : 79-87, 1984
• 9 Seo, K.K., "Intracavernosl self-injection therapy for the patients with erectile dysfunction: comparison of erectile response and complications between bimix and trimix solution" 38 : 306-311, 1997
• 10 Alexandre, B., "Intracaver- nous injections of prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life on long-term treatment" 4 : 426-431, 2007
• 11 Barada, J.H., "Impotence 1st ed" Saunders 229-250, 1994
• 12 Kim, I.G., "Eretile response to intracavernosal injection of Alprostadil (Caverject) in impotent Patients" 13 : 113-122, 1995
• 13 Lee, Y.S., "Erectile response of intracavernous injection of new triple agents, chlorpromazine, papaverine, and alprostadil" 44 : 1121-1123, 2003
• 14 Jeon, H.J., "Efficacy and preference of sildenafil in patients on trimix intracavernous injection" 43 : 976-979, 2002
• 15 Althof, S.E., "EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction" 53 : 793-799, 1999
• 16 Hatzichristou, D.G., "Current treatments and emerging therapeutic approaches in male erectile dysfunc- tion" 88 : 11-17, 2001
• 17 Kim, S.C., "Chemical stability of lyophilized papaverine/phentolamine/alprostadil (Standro®)" 21 : 23-26, 2003
• 18 Zorgniotti, A.W., "Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence" 133 : 39-41, 1985
• 19 Breivik, H., "Assessment of pain" 101 : 17-24, 2008
• 20 Bennett, A.H., "An improved vasoactive drug combination for a pharmacological erection program" 146 : 1564-1565, 1991